A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, Preliminary Efficacy of KNT-0916 in Subjects with Unresectable or Metastatic Solid Tumors with FGFR2 Alterations
Latest Information Update: 06 Feb 2025
At a glance
- Drugs KNT 0916 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 06 Feb 2025 New trial record